Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and...

Idera Pharmaceuticals Acquires Aceragen Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00...

Seeking Innovators to Defend Against Chemical and Biological Weapons Fort Belvoir, Virginia, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Collaboration between government, academia and industry is key to defending our warfighters and nation from the evolving threat of weapons...